Panbela Therapeutics, Inc. (PBLA)
| Previous Close | 0.5900 |
| Open | 0.5500 |
| Bid | 0.0000 x 900 |
| Ask | 0.0000 x 1200 |
| Day's Range | 0.5001 - 0.5875 |
| 52 Week Range | 0.4110 - 477.0000 |
| Volume | |
| Avg. Volume | 723,669 |
| Market Cap | 2.622M |
| Beta (5Y Monthly) | 0.78 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -316.5200 |
| Earnings Date | May 02, 2024 - May 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 252.50 |
GlobeNewswirePanbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter and full year ended December 31, 2023. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. 2023 and early 2024 Highlights: Collaborations Divestiture of Assets within Eflornith
- GlobeNewswire
Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024
MINNEAPOLIS, March 12, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on March 26, 2024, at 4:30 PM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code:
- GlobeNewswire
Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares Requirements
MINNEAPOLIS, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market (“Nasdaq”) for bid price and publicly held shares. Nasdaq has issued notice that Panbela has regained compliance for continued listing of its common stock. On February
